glp-1 obesity drug news today october 23 2025 How to Invest in Drugs: Stocks and Funds to Watch Could GLP-1 Weight Loss Drugs

"And as we're treating them, we are going to trace and see how the immune cells are behaving," Omene says

[DOI] [PMC free article] [PubMed] [Google Scholar] 535.Chen H., Gu X., Su I.H., Bottino R., Contreras J.L., Tarakhovsky A

BDP has no conflicts of interest to disclose

Kahles F, Liberman A, Halim C, Rau M, Mollmann J, Mertens RW, Ruckbeil M, Diepolder I, Walla B, Diebold S, et al

About Press Copyright Contact us Creators Advertise Developers Cancel Memberships Terms Privacy Policy & Safety How YouTube works Test new features 2026 Google LLC

Amgen is developing a GLP-1/GIP dual agonist called MariTide (currently in phase 3 trials expected to complete in 2027), which is administered as a once-monthly injection